Yu Hua Chen

US Patent:

7091396, Aug 15, 2006

Filed:

Oct 17, 2001

Appl. No.:

09/982120

Inventors:

Sanford M. Simon - New York NY, US
Yu Chen - New York NY, US

Assignee:

The Rockefeller University - New York NY

International Classification:

A01K 67/027
A01K 67/033
C12N 15/63
C12N 5/06
C12N 5/10

US Classification:

800 18, 800 13, 435326, 435325, 435455, 4353201

Abstract:

Genetically-modified mammals and immune cells are provided which are capable of producing or secreting detectably-labeled immunoglobulin molecules as a result of genetic modifications of at least one immunoglobulin gene in the genome thereof, such that a fusion polynucleotide encoding a detectable protein or peptide and an immunoglobulin component molecule is present.

US Patent:

20030049597, Mar 13, 2003

Filed:

Mar 1, 2001

Appl. No.:

09/797496

Inventors:

Sanford Simon - New York NY, US
Yu Chen - New York NY, US

International Classification:

C12Q001/00
C12Q001/37
C12N015/87

US Classification:

435/004000, 435/023000, 435/455000

Abstract:

Method for similtaneously quantifying in situ the relationship between an enzyme and its substrate, especially by the use of fluorescence.

US Patent:

20060288430, Dec 21, 2006

Filed:

Jun 23, 2006

Appl. No.:

11/474133

Inventors:

Sanford Simon - New York NY, US
Yu Chen - New York NY, US

International Classification:

A01K 67/027

US Classification:

800006000, 800014000

Abstract:

Genetically-modified mammals and immune cells are provided which are capable of producing or secreting detectably-labeled immunoglobulin molecules as a result of genetic modifications of at least one immunoglobulin gene in the genome thereof, such that a fusion polynucleotide encoding a detectable protein or peptide and an immunoglobulin component molecule is present.

US Patent:

20090193530, Jul 30, 2009

Filed:

Dec 12, 2008

Appl. No.:

12/316433

Inventors:

Sanford M. Simon - New York NY, US
Yu Chen - New York NY, US

International Classification:

A01K 67/027
C12N 15/85
C12N 5/06
C07K 16/18

US Classification:

800 6, 800 14, 435328, 5303917

Abstract:

Genetically-modified mammals and immune cells are provided which are capable of producing or secreting detectably-labeled immunoglobulin molecules as a result of genetic modifications of at least one immunoglobulin gene in the genome thereof, such that a fusion polynucleotide encoding a detectable protein or peptide and an immunoglobulin component molecule is present.

US Patent:

62040677, Mar 20, 2001

Filed:

Jun 17, 1999

Appl. No.:

9/335457

Inventors:

Sanford M. Simon - New York NY
Melvin S. Schindler - Okemos MI
Yu Chen - New York NY

Assignee:

Board of Trustees Operating Michigan State University - East Lansing MI

International Classification:

G01N 3122
G01N 2180
G01N 3348
C07C21104

US Classification:

436163

Abstract:

The present invention discloses the mechanism of tamoxifen mediated inhibition of acidification. This mechanism information is then used to design methods of identifying compounds that will have the pharmaceutical effect of tamoxifen without the corresponding side-effects.

US Patent:

20190292529, Sep 26, 2019

Filed:

Jan 25, 2019

Appl. No.:

16/258477

Inventors:

- New York NY, US
Thomas WIESNER - New York NY, US
Yu CHEN - New York NY, US

Assignee:

Memorial Sloan Kettering Cancer Center - New York NY

International Classification:

C12N 9/12
A61K 31/5377
A61K 31/545
G01N 33/574
A61K 31/4545
C12Q 1/6886
A61K 31/506

Abstract:

The present invention relates to a Truncated isoform of Anaplastic Lymphoma Kinase (“TALK”). Expression of this isoform is associated with malignancy and with responsiveness to ALK inhibitors. Detection of the isoform may be used in diagnostic and therapeutic methods. Because it arises as a result of variant transcription rather than genetic rearrangement, its presence would be undetected by genomic testing.

US Patent:

20180038933, Feb 8, 2018

Filed:

Oct 16, 2017

Appl. No.:

15/785343

Inventors:

- Evanston IL, US
Yu Fen Chen - Chicago IL, US

International Classification:

G01R 33/563
G01R 33/50

Abstract:

Described here are systems and methods for obtaining measurements of both tissue perfusion and permeability with a magnetic resonance imaging (“MRI”) system after the administration of a single dose of contrast agent. To this end, the MRI system is directed to acquire T2-weighted or T2*-weighted data, during which the acquired signal values are monitored for a trigger event. When the trigger event occurs, the MRI system is directed to switch from acquiring the T2-weighted or T2*-weighted data to acquiring T1-weighted data. The systems and methods described here can thus be used for a fully automated, single acquisition of perfusion and permeability measurements using only a single dose of contrast agent.

US Patent:

20170022485, Jan 26, 2017

Filed:

Oct 7, 2016

Appl. No.:

15/288531

Inventors:

- New York NY, US
Thomas Wiesner - New York NY, US
Yu Chen - New York NY, US

International Classification:

C12N 9/12
A61K 31/506
A61K 31/4545
G01N 33/574
C12Q 1/68

Abstract:

The present invention relates to a runcated isoform of naplastic ymphoma inase (“TALK”). Expression of this isoform is associated with malignancy and with responsiveness to ALK inhibitors. Detection of the isoform may be used in diagnostic and therapeutic methods. Because it arises as a result of variant transcription rather than genetic rearrangement, its presence would be undetected by genomic testing.

Address:

4631 66 St, Woodside, NY 11377

VIN:

1G6DW677370185003

Make:

CADILLAC

Model:

STS

Year:

2007